On March 16, 2026, Annovis Bio, Inc. (NYSE: ANVS) announced its financial results for the fiscal year ending December 31, 2025, alongside significant updates on its clinical development programs. The company reported a net loss of $28.85 million, or $1.40 per share, for the year, an improvement from a net loss of $24.59 million, or $2.02 per share, in 2024. Research and development expenses increased to $25.2 million from $20 million in the previous year, reflecting the company's commitment to advancing its lead drug candidate, buntanetap, through pivotal clinical trials.

In 2025, Annovis initiated a pivotal Phase 3 clinical trial for early Alzheimer's disease (AD) and launched an open-label extension study for Parkinson's disease (PD). The company reported encouraging data from its previous trials, indicating potential disease-modifying effects of buntanetap, which targets neurotoxic proteins associated with neurodegenerative diseases. CEO Maria Maccecchini emphasized the importance of these milestones in the company's journey towards submitting a New Drug Application (NDA).

Annovis also highlighted its financial position, with cash and cash equivalents totaling $19.5 million as of December 31, 2025, up from $10.6 million in 2024. This funding is expected to support operations into the third quarter of 2026. The company continues to focus on rigorous clinical trial execution while maintaining a strong scientific presence in the field through conferences and publications.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.